Epistatic interactions within the influenza A virus polymerase complex mediate mutagen resistance and replication fidelity

mSphere

Volumn 2, Issue 4, 2017, Pages

  Pauly, Matthew D ^a   Lyons, Daniel M ^b   Fitzsimmons, William J ^a   Lauring, Adam S ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Evolution; Influenza; Mutagenesis; Polymerase; Virus

Indexed keywords

EID: 85041525519     PISSN: None     EISSN: 23795042     Source Type: Journal    
DOI: 10.1128/mSphere.00323-17     Document Type: Article

References (60)

1. Nelson MI, Holmes EC. 2007. The evolution of epidemic influenza. Nat Rev Genet 8:196-205. https://doi.org/10.1038/nrg2053
2. Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. 1986. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J Virol 59:377-383
3. Nobusawa E, Sato K. 2006. Comparison of the mutation rates of human influenza A and B viruses. J Virol 80:3675-3678. https://doi.org/10.1128/ JVI.80.7.3675-3678.2006
4. Suárez-López P, Ortín J. 1994. An estimation of the nucleotide substitution rate at defined positions in the influenza virus haemagglutinin gene. J Gen Virol 75:389-393. https://doi.org/10.1099/0022-1317-75-2-389
5. Suárez P, Valcárcel J, Ortín J. 1992. Heterogeneity of the mutation rates of influenza A viruses: isolation of mutator mutants. J Virol 66: 2491-2494
6. Paules C, Subbarao K. 2017. Influenza. Lancet https://doi.org/10.1016/ S0140-6736(17)30129-0
7. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis. Lancet Infect Dis 12:36-44. https://doi.org/10.1016/S1473-3099 (11)70295-X
8. Steinhauer DA, Domingo E, Holland JJ. 1992. Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 122:281-288. https://doi.org/10.1016/0378-1119(92)90216-C
9. Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. 2013. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 9:e1003565. https://doi.org/10.1371/journal.ppat.1003565
10. Smith EC, Sexton NR, Denison MR. 2014. Thinking outside the triangle: replication fidelity of the largest RNA viruses. Annu Rev Virol 1:111-132. https://doi.org/10.1146/annurev-virology-031413-085507
11. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97:6108-6113. https://doi.org/10 .1073/pnas.100133697
12. Bloom JD. 2014. An experimentally determined evolutionary model dramatically improves phylogenetic fit. Mol Biol Evol 31:1956-1978. https://doi.org/10.1093/molbev/msu173
13. Pauly MD, Procario MC, Lauring AS. 2017. A novel twelve class fluctuation test reveals higher than expected mutation rates for influenza A viruses. eLife 6:686. https://doi.org/10.7554/eLife.26437
14. Sanjuán R. 2010. Mutational fitness effects in RNA and single-stranded DNA viruses: common patterns revealed by site-directed mutagenesis studies. Philos Trans R Soc Lond B Biol Sci 365:1975-1982. https://doi .org/10.1098/rstb.2010.0063
15. Visher E, Whitefield SE, McCrone JT, Fitzsimmons W, Lauring AS. 2016. The mutational robustness of influenza A virus. PLoS Pathog 12: e1005856. https://doi.org/10.1371/journal.ppat.1005856
16. Anderson JP, Daifuku R, Loeb LA. 2004. Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol 58:183-205. https://doi.org/ 10.1146/annurev.micro.58.030603.123649
17. Bull JJ, Sanjuán R, Wilke CO. 2007. Theory of lethal mutagenesis for viruses. J Virol 81:2930-2939. https://doi.org/10.1128/JVI.01624-06
18. Lee CH, Gilbertson DL, Novella IS, Huerta R, Domingo E, Holland JJ. 1997. Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus. J Virol 71:3636-3640
19. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 98:6895-6900. https://doi.org/10.1073/pnas.111085598
20. Loeb LA, Mullins JI. 2000. Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. AIDS Res Hum Retroviruses 16:1-3. https://doi .org/10.1089/088922200309539
21. Grande-Pérez A, Sierra S, Castro MG, Domingo E, Lowenstein PR. 2002. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc Natl Acad Sci U S A 99:12938-12943. https:// doi.org/10.1073/pnas.182426999
22. Cheung PPH, Watson SJ, Choy KT, Fun Sia S, Wong DDY, Poon LLM, Kellam P, Guan Y, Malik Peiris JS, Yen HL. 2014. Generation and characterization of influenza A viruses with altered polymerase fidelity. Nat Commun 5:4794. https://doi.org/10.1038/ncomms5794
23. Pauly MD, Lauring AS. 2015. Effective lethal mutagenesis of influenza virus by three nucleoside analogs. J Virol 89:3584-3597. https://doi.org/ 10.1128/JVI.03483-14
24. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741-3751. https://doi.org/ 10.1128/JVI.02346-12
25. Graham AF, Kirk C. 1965. Effect of 5-fluorouracil on the growth of bacteriophage R17. J Bacteriol 90:928-935
26. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986. https://doi.org/10.1128/AAC.49.3.981-986.2005
27. Vanderlinden E, Vrancken B, Van Houdt J, Rajwanshi VK, Gillemot S, Andrei G, Lemey P, Naesens L. 2016. Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother 60:6679-6691. https://doi.org/10.1128/ AAC.01156-16
28. Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Norén JO, Philipson L, Stenberg K, Stening G, Stridh S, Oberg B. 1977. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 11:946-951. https://doi.org/10.1128/AAC .11.6.946
29. Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A 100:7289-7294. https://doi.org/10.1073/pnas.1232294100
30. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344-348. https://doi.org/10.1038/ nature04388
31. Coffey LL, Beeharry Y, Bordería AV, Blanc H, Vignuzzi M. 2011. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc Natl Acad Sci U S A 108:16038-16043. https://doi.org/10.1073/pnas.1111650108
32. Zeng J, Wang H, Xie X, Yang D, Zhou G, Yu L. 2013. An increased replication fidelity mutant of foot-and-mouth disease virus retains fitness in vitro and virulence in vivo. Antiviral Res 100:1-7. https://doi.org/ 10.1016/j.antiviral.2013.07.008
33. Zeng J, Wang H, Xie X, Li C, Zhou G, Yang D, Yu L. 2014. Ribavirinresistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence. J Virol 88:4008-4020. https:// doi.org/10.1128/JVI.03594-13
34. Sierra M, Airaksinen A, González-López C, Agudo R, Arias A, Domingo E. 2007. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol 81:2012-2024. https://doi.org/10.1128/JVI.01606-06
35. Agudo R, Ferrer-Orta C, Arias A, de la Higuera I, Perales C, Pérez-Luque R, Verdaguer N, Domingo E. 2010. A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog 6:e1001072. https://doi .org/10.1371/journal.ppat.1001072
36. Perales C, Agudo R, Domingo E. 2009. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS One 4:e5554. https://doi.org/10.1371/ journal.pone.0005554
37. Agudo R, de la Higuera I, Arias A, Grande-Pérez A, Domingo E. 2016. Involvement of a joker mutation in a polymerase-independent lethal mutagenesis escape mechanism. Virology 494:257-266. https://doi.org/ 10.1016/j.virol.2016.04.023
38. Pereira-Gómez M, Sanjuán R. 2014. Delayed lysis confers resistance to the nucleoside analogue 5-fluorouracil and alleviates mutation accumulation in the single-stranded DNA bacteriophage ϕX174. J Virol 88: 5042-5049. https://doi.org/10.1128/JVI.02147-13
39. Elena SF. 2012. RNA virus genetic robustness: possible causes and some consequences. Curr Opin Virol 2:525-530. https://doi.org/10.1016/j .coviro.2012.06.008
40. Graci JD, Gnädig NF, Galarraga JE, Castro C, Vignuzzi M, Cameron CE. 2012. Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis. J Virol 86:2869-2873. https://doi.org/10.1128/JVI .05712-11
41. Lauring AS, Acevedo A, Cooper SB, Andino R. 2012. Codon usage determines the mutational robustness, evolutionary capacity, and virulence of an RNA virus. Cell Host Microbe 12:623-632. https://doi.org/10 .1016/j.chom.2012.10.008
42. te Velthuis AJW, Fodor E. 2016. Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nat Rev Microbiol 14: 479-493. https://doi.org/10.1038/nrmicro.2016.87
43. Binh NT, Wakai C, Kawaguchi A, Nagata K. 2014. Involvement of the N-terminal portion of influenza virus RNA polymerase subunit PB1 in nucleotide recognition. Biochem Biophys Res Commun 443:975-979. https://doi.org/10.1016/j.bbrc.2013.12.071
44. Binh NT, Wakai C, Kawaguchi A, Nagata K. 2013. The N-terminal region of influenza virus polymerase PB1 adjacent to the PA binding site is involved in replication but not transcription of the viral genome. Front Microbiol 4:398. https://doi.org/10.3389/fmicb.2013.00398
45. Naito T, Mori K, Ushirogawa H, Takizawa N, Nobusawa E, Odagiri T, Tashiro M, Ohniwa RL, Nagata K, Saito M. 2017. Generation of a genetically stable high-fidelity influenza vaccine strain. J Virol 91:e01073-16. https://doi.org/10.1128/JVI.01073-16
46. Pflug A, Guilligay D, Reich S, Cusack S. 2014. Structure of influenza A polymerase bound to the viral RNA promoter. Nature 516:355-360. https://doi.org/10.1038/nature14008
47. Reich S, Guilligay D, Pflug A, Malet H, Berger I, Crépin T, Hart D, Lunardi T, Nanao M, Ruigrok RWH, Cusack S. 2014. Structural insight into capsnatching and RNA synthesis by influenza polymerase. Nature 516: 361-366. https://doi.org/10.1038/nature14009
48. Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE. 2005. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem 280:25706-25716. https://doi.org/10 .1074/jbc.M503444200
49. Korneeva VS, Cameron CE. 2007. Structure-function relationships of the viral RNA-dependent RNA polymerase: fidelity, replication speed, and initiation mechanism determined by a residue in the ribose-binding pocket. J Biol Chem 282:16135-16145. https://doi.org/10.1074/jbc .M610090200
50. Campagnola G, McDonald S, Beaucourt S, Vignuzzi M, Peersen OB. 2015. Structure-function relationships underlying the replication fidelity of viral RNA-dependent RNA polymerases. J Virol 89:275-286. https://doi .org/10.1128/JVI.01574-14
51. Arias A, Arnold JJ, Sierra M, Smidansky ED, Domingo E, Cameron CE. 2008. Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-andmouth disease virus mutant with reduced sensitivity to ribavirin. J Virol 82:12346-12355. https://doi.org/10.1128/JVI.01297-08
52. Lauring AS, Frydman J, Andino R. 2013. The role of mutational robustness in RNA virus evolution. Nat Rev Microbiol 11:327-336. https://doi .org/10.1038/nrmicro3003
53. Marsh GA, Hatami R, Palese P. 2007. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J Virol 81:9727-9736. https://doi.org/10.1128/ JVI.01144-07
54. Baker SF, Nogales A, Finch C, Tuffy KM, Domm W, Perez DR, Topham DJ, Martínez-Sobrido L. 2014. Influenza A and B virus intertypic reassortment through compatible viral packaging signals. J Virol 88:10778-10791. https://doi.org/10.1128/JVI.01440-14
55. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. 2001. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 146:2275-2289. https://doi.org/10.1007/s007050170002
56. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59. https://doi.org/10.1016/0378-1119(89)90358-2
57. Martínez-Sobrido L, Cadagan R, Steel J, Basler CF, Palese P, Moran TM, García-Sastre A. 2010. Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J Virol 84:2157-2163. https://doi.org/10.1128/JVI .01433-09
58. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493-497
59. Furió V, Moya A, Sanjuán R. 2005. The cost of replication fidelity in an RNA virus. Proc Natl Acad Sci U S A 102:10233-10237. https://doi.org/ 10.1073/pnas.0501062102
60. Foster PL. 2006. Methods for determining spontaneous mutation rates. Methods Enzymol 409:195-213. https://doi.org/10.1016/S0076-6879 (05)09012-9